Vertex Pharmaceuticals (VRTX) Free Cash Flow (2009 - 2026)

Vertex Pharmaceuticals' Free Cash Flow history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Free Cash Flow rose 66.37% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $3.7 billion (up 396.75% YoY), while the FY2025 annual figure was $3.2 billion, up 504.13% from the prior year.
• Free Cash Flow for Q1 2026 stood at $1.3 billion, up from $348.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $1.3 billion in Q3 2024, with the low at -$3.8 billion in Q2 2024.
• The 5-year median for Free Cash Flow is $927.4 million (2025), against an average of $644.7 million.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 535.3% in 2022, then tumbled 455.66% in 2024.
• Vertex Pharmaceuticals' Free Cash Flow stood at $1.0 billion in 2022, then plunged by 83.11% to $176.5 million in 2023, then jumped by 178.75% to $492.0 million in 2024, then declined by 29.15% to $348.6 million in 2025, then surged by 271.4% to $1.3 billion in 2026.
• Business Quant data shows VRTX's Free Cash Flow at $1.3 billion in Q1 2026, $348.6 million in Q4 2025, and $1.1 billion in Q3 2025.